The Federal Trade Commission reached a settlement with Caremark on July 14, 2026, resolving an antitrust case against one of the largest pharmacy benefit managers in the United States.
The FTC said the agreement covers Caremark and its affiliated entities. The agency described the action as its second against a drug middleman of this kind.
According to the FTC, the settlement is designed to reduce patients' out-of-pocket drug costs, increase transparency in pharmacy benefit management, and ensure that community pharmacies are treated fairly.
The commission framed the agreement as part of a broader effort to lower healthcare costs for Americans.